

12-10-01

ATTORNEY DOCKET NO. B080117231 (ERP/KA)

A/B080117231

JCS98 U.S. PTO

11/08/01

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications  
under 37 CFR 1.53(b))Attorney Docket No. **B0801/7231**

First Named Inventor or Application Identifier

Richard T. Lee

Express Mail Label No.

EL840384892US

Date of Deposit

November 8, 2001

JCS98 U.S. PTO  
11/02/01

11/02/01

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

1. ☒ Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.  
☐ Statement filed in prior application, status still proper and desired.
3. ☒ Specification [Total pages 76, excl. seq. List]  
69 - pages description  
1 - page abstract  
6 - pages claims 36 - Total claims  
34 - pages sequence list
4. ☒ Drawing(s) (35 USC 113) - Total sheets 6  
☒ Informal ☐ Formal Figs. 1-11
5. ☐ Oath or Declaration - Total pages  
a. ☐ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 18 completed)  
[Note Box 6 below]  
i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Incorporation by Reference  
(usable if Box 5b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. See 19.
7. ☒ Application Data Sheet, See 37 CFR 1.76

ADDRESS  
TO:Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

8. ☐ CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix)
9. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  
a. ☒ Computer Readable Form (CRF)  
b. ☒ Specification Sequence Listing on:  
i. ☐ CD-ROM or CD-R (2 copies); or  
ii. ☒ paper (identical to computer copy)  
c. ☒ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

10. ☐ Assignment Papers/cover sheet & documents(s)
11. ☐ 37 CFR 3.73(b) Statement  
(when there is an assignee)  
☐ Power of Attorney
12. ☐ English Translation of Document (if applicable)
13. ☐ Information Disclosure Statement/PTO-1449  
☐ Copies of IDS Citations
14. ☒ Preliminary Amendment
15. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
16. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
17. ☐ Request and Certification Under 35 U.S.C. §122(b)(2)(B)(ii)
18. ☒ Other: This application claims priority under 35 U.S.C. §119(e) from Provisional U.S. Patent Application Serial No. 60/247,457 filed on November 9, 2000, entitled CARDIOVASCULAR DISEASE DIAGNOSTIC AND THERAPEUTIC TARGETS. The contents of the provisional application are hereby expressly incorporated by reference.

19. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_, filed on \_\_\_\_\_, entitled \_\_\_\_\_ and now \_\_\_\_\_.

☐ Cancel in this application claims \_\_\_\_\_ before calculating the filing fee.

☐ Amend the specification by inserting before the first line of the specification on page 1, after the title, the following:

--This application is a ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_, filed on \_\_\_\_\_, entitled \_\_\_\_\_ and now \_\_\_\_\_.

Prior application information: Examiner \_\_\_\_\_ Group Art Unit: \_\_\_\_\_

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

20. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER:



23628

OR

ATTORNEY'S NAME	Elizabeth Robin Plumer, Reg. No. 36,637				
FIRM NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441
20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED					
NAME	Elizabeth Robin Plumer, Reg. No. 36,637				
SIGNATURE					
DATE	November 8, 2001				

Inventor or Identifier: Richard T. Lee  
 Serial No: Not yet assigned

Filed: Herewith

For: CARDIOVASCULAR DISEASE DIAGNOSTIC AND  
 THERAPEUTIC TARGETS

CHECK BOX, if applicable:

☐ DUPLICATE

Fee Calculation Sheet

CLAIMS	FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
	TOTAL CLAIMS (37 CFR 1.16(c))	20-20=	0 x	\$18	= \$ .00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	8-3=	5 x	\$80	= \$ 400.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d)) +			\$260	= \$
				BASIC FEE (37 CFR 1.16(a))	\$ 710.00
	Total of above Calculations =				\$ 1,110.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).				\$ 1,110.00
	Assignment Recordation Fee (if any)				\$
	Other Fees (if any).				\$
	TOTAL =				\$ 1,110.00

1. A check in the amount of \$ 1,110.00 is enclosed.

**General Authorization to Charge Deposit Account and General Request for Extension of Time**

2. a. ☒ If the filing of any paper in this application necessitates the payment of a fee under 37 CFR §§ 1.16 or 1.17, and the fee due is in an amount different from any enclosed check or if no check is enclosed, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.

b. ☐ The applicant hereby revokes any prior authorization to charge a fee due under 37 CFR §§ 1.16 or 1.17 or 1.18.

3. If the filing of any paper in this application necessitates an extension of time under 37 CFR § 1.136(a), the applicant hereby requests such extension of time. If the fee due is in an amount different from any enclosed check or if no check is enclosed, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.

*Elizabeth Robin Plumer*  
 Elizabeth Robin Plumer, Reg. No. 36,637  
 Wolf, Greenfield & Sacks, P.C.  
 600 Atlantic Avenue  
 Boston, MA 02210-2211  
 (617) 720-3500  
 Attorneys of Record

Docket No. B0801/7231  
 Date: November 8, 2001

Express Mail Label No.: EL 840384892 US  
Date of Deposit: November 8, 2001  
Attorney Docket No.: B0801/7231 (ERP/KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Richard T. LEE  
Serial No: Not yet assigned  
Filed: Herewith  
For: CARDIOVASCULAR DISEASE DIAGNOSTIC AND THERAPEUTIC  
TARGETS  
Examiner: Not yet assigned  
Art Unit: Not yet assigned


Box Patent Application  
Commissioner For Patents  
Washington, D.C. 20231

Sir:

STATEMENT PURSUANT TO 37 C.F.R. §1.821(f)

This statement is made pursuant to 37 C.F.R. §1.821(f). Applicant enclose herewith an written copy and a computer readable copy of the Sequence Listing. Applicant's attorney states that the information recorded in the computer readable copy is identical to the written copy of the Sequence Listing.

Respectfully submitted,



Elizabeth R. Plumer, Reg. No. 36,637  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
(617) 720-3500

Attorney Docket No.: B0801/7231 (ERP/KA)  
Date: November 8, 2001  
x11/09/01x